Abbott Secures FDA Clearance for SimpleScreen CRC, a Non-Invasive Cancer Test

Abbott Laboratories received FDA clearance for its SimpleScreen CRC blood test on July 27, 2026.

The diagnostic tool detects colorectal cancer in average-risk adults aged 45 and older.

This blood-based method provides a less invasive alternative to traditional colonoscopies.

Abbott will launch the test exclusively in the United States this fall.